- Home
- REE vs BIVI Comparison
REE vs BIVI Comparison
Compare REE & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REE
- BIVI
- Stock Information
- Founded
- REE 2011
- BIVI 2013
- Country
- REE Israel
- BIVI United States
- Employees
- REE N/A
- BIVI N/A
- Industry
- REE Auto Manufacturing
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- REE Consumer Discretionary
- BIVI Health Care
- Exchange
- REE Nasdaq
- BIVI Nasdaq
- Market Cap
- REE 18.5M
- BIVI 15.0M
- IPO Year
- REE N/A
- BIVI N/A
- Fundamental
- Price
- REE $0.69
- BIVI $1.65
- Analyst Decision
- REE Strong Buy
- BIVI
- Analyst Count
- REE 2
- BIVI 0
- Target Price
- REE $11.75
- BIVI N/A
- AVG Volume (30 Days)
- REE 85.2K
- BIVI 383.9K
- Earning Date
- REE 09-25-2025
- BIVI 09-29-2025
- Dividend Yield
- REE N/A
- BIVI N/A
- EPS Growth
- REE N/A
- BIVI N/A
- EPS
- REE N/A
- BIVI N/A
- Revenue
- REE $183,000.00
- BIVI N/A
- Revenue This Year
- REE $6,661.20
- BIVI N/A
- Revenue Next Year
- REE $2,240.01
- BIVI N/A
- P/E Ratio
- REE N/A
- BIVI N/A
- Revenue Growth
- REE N/A
- BIVI N/A
- 52 Week Low
- REE $0.53
- BIVI $1.52
- 52 Week High
- REE $11.72
- BIVI $75.00
- Technical
- Relative Strength Index (RSI)
- REE 45.75
- BIVI 19.17
- Support Level
- REE $0.65
- BIVI $1.60
- Resistance Level
- REE $0.73
- BIVI $1.84
- Average True Range (ATR)
- REE 0.05
- BIVI 0.52
- MACD
- REE 0.01
- BIVI -0.30
- Stochastic Oscillator
- REE 55.42
- BIVI 2.30
About REE REE Automotive Ltd.
REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is in early stages of commercialization and develop and produce software-defined vehicle (SDV) technology that manages vehicle operations and features through proprietarily-developed software. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.